MRD assessments are probably 1 of the most powerful predictors that we have to see how well a treatment has worked, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
MRD assessments are probably 1 of the most powerful predictors that we have to see how well a treatment has worked, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Transcript
How accurate is MRD assessment at judging how deep remission is or how well a treatment worked?
So, it's actually very accurate. It's probably 1 of the most powerful predictors that we have to see how well a treatment has worked. In fact, most patients that do not achieve a complete remission will be minimal residual disease positive so that just tells you how good that is. There could be some instances, which are not many, where a patient could have what we call extramedullary disease—it’s a patient with multiple myeloma [who] comes in and has some mass or something somewhere, for example, in the ribs. It's not uncommon to have lesions in the bones that maybe have a little bit of a mass and then you treat the patient, and you do your MRD assessment in the bone marrow, which is basically just taking a little bit of blood from the bone marrow, maybe like a couple of millimeters or something like that.
Then you test that and that's negative, but then you do a PET CT or you do an MRI and you still see that there is something left in terms of where that rib lesion had been. So, in that situation, the patient obviously is not yet in remission—I mean, there's myeloma left, and you can treat that and keep checking the MRD, but sometimes there are some situations where MRD may tell you that it's negative, but there may be some residual disease; but these are not most of the situations in myeloma. So this is why again, for the response criteria, there's an imaging and MRD negativity. So, you can also do some imaging like whole body imaging, whole body PET CT is useful in these circumstances, as would be MRI.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Kathy Oubre on Strategies to Mitigate Challenges When Adopting New Payment Models
February 23rd 2024While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.
Read More
Getting to Know Dr Shauna Downs, Public Health Nutritionist
February 23rd 2024Shauna Downs, PhD, MS, is an associate professor in the Department of Health Behavior, Society, and Policy at the Rutgers School of Public Health. A former figure skater, her research now focuses on interventions to promote healthy and sustainable food choices and exploring how our changing climate, food systems, diet, and nutrition are inextricably linked.
Read More